HC Wainwright Has Bearish Forecast for DAWN FY2028 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Equities research analysts at HC Wainwright lowered their FY2028 earnings estimates for Day One Biopharmaceuticals in a report released on Wednesday, May 7th. HC Wainwright analyst A. Maldonado now expects that the company will post earnings per share of $0.74 for the year, down from their previous estimate of $0.84. HC Wainwright has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ FY2029 earnings at $1.25 EPS.

DAWN has been the subject of a number of other research reports. Wedbush restated an “outperform” rating and issued a $25.00 price target on shares of Day One Biopharmaceuticals in a report on Wednesday. JPMorgan Chase & Co. lowered their price target on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating for the company in a report on Wednesday, March 5th. The Goldman Sachs Group cut their price objective on shares of Day One Biopharmaceuticals from $39.00 to $27.00 and set a “buy” rating on the stock in a report on Tuesday, March 25th. Finally, Needham & Company LLC lowered their target price on Day One Biopharmaceuticals from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Wednesday. Seven analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $30.57.

Day One Biopharmaceuticals Price Performance

Shares of NASDAQ DAWN opened at $6.45 on Thursday. Day One Biopharmaceuticals has a 1-year low of $6.26 and a 1-year high of $17.14. The company has a market capitalization of $653.73 million, a price-to-earnings ratio of -6.26 and a beta of -1.24. The business has a 50-day moving average of $7.70 and a 200-day moving average of $11.10.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its earnings results on Tuesday, May 6th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.11. The business had revenue of $30.76 million for the quarter, compared to analyst estimates of $30.28 million.

Insiders Place Their Bets

In related news, General Counsel Adam Dubow sold 4,646 shares of the business’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares of the company’s stock, valued at $473,639.92. This represents a 10.50 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Jeremy Bender sold 12,048 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $144,094.08. Following the sale, the chief executive officer now owns 128,015 shares in the company, valued at approximately $1,531,059.40. This trade represents a 8.60 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 21,064 shares of company stock valued at $251,925 in the last quarter. Insiders own 6.20% of the company’s stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several large investors have recently added to or reduced their stakes in the stock. FMR LLC grew its position in shares of Day One Biopharmaceuticals by 73.9% during the fourth quarter. FMR LLC now owns 12,887,467 shares of the company’s stock worth $163,284,000 after acquiring an additional 5,475,087 shares during the last quarter. Alyeska Investment Group L.P. acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,829,000. Boxer Capital Management LLC bought a new stake in shares of Day One Biopharmaceuticals during the fourth quarter valued at approximately $15,077,000. Marshall Wace LLP acquired a new position in shares of Day One Biopharmaceuticals during the fourth quarter worth approximately $13,909,000. Finally, Estuary Capital Management LP grew its holdings in Day One Biopharmaceuticals by 35.5% in the 4th quarter. Estuary Capital Management LP now owns 3,716,777 shares of the company’s stock worth $47,092,000 after buying an additional 972,997 shares in the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.